Trial Profile
A Randomized, Double-Blind, Parallel Study of the effects on asthma control of a Once Daily Dosing of EPI-12323 versus Placebo in Symptomatic Moderate to Severe Asthmatics on Low-Dose Inhaled Corticosteroids
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jun 2016
Price :
$35
*
At a glance
- Drugs EPI 12323 (Primary) ; Budesonide
- Indications Asthma
- Focus Therapeutic Use
- Sponsors EpiGenesis Pharmaceuticals
- 08 Jun 2016 Status changed from not yet recruiting to completed.
- 11 Jul 2011 New trial record